$ALMU

Denbaars Steven sold $346K of ALMU

Denbaars Steven sold 25,000 shares of Aeluma, Inc. (ALMU) at an average of $13.83 ($13.82–$13.84, $0.35M total) across 2 trades over 2026-08-26 to 2026-08-27.

Original reporting
SEC EDGAR · Denbaars Steven
Published Aug 28, 2026, 8:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMU
Bearish
medium confidence
Mentioned
$ALMU
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMUBearishLow
01

Why it matters

A director's sale may prompt short‑term traders to consider selling pressure, but the retained holdings mitigate concerns.

02

Market read

Insider sale of $346K is a modest but noteworthy event for a micro‑cap biotech.

03

What to watch

The director retains a sizable stake, indicating continued confidence.

Relevance 4/10Novelty 4/10Timing: filed on 2026-08-28

Background

Form 4 filings disclose insider transactions; investors monitor them for potential signals.

Company-level read

Ticker impact

$ALMUBearishMedium confidence
Context

Director Steven Denbaars sold 25,000 shares for $345,741, reducing his stake to 345,209 shares.

Expected impact

Possible modest downside pressure in the next few days.

Evidence & confidence

A $346K sale by a director is material for a micro‑cap, but the amount is modest relative to market cap.

Market effects

Minimal impact on the broader biotech sector.

Limited to U.S. investors tracking insider activity.

None

Counterpoint

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Aeluma, Inc.

    Biotech firm listed on NASDAQ under ticker ALMU.

  • Steven Denbaars

    Director of Aeluma who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

High

Why is Aeluma stock surging today?

Aeluma stock rose 7.0% in pre-market trading after announcing a partnership with Sumitomo Chemical Advanced Technologies to develop and manufacture photonics wafers for AI datacom. The company is set to report Q4 and full-year 2026 earnings on September 16. The sole analyst's price target of $30.50 suggests significant upside from current levels.

$ALMUMed

The Speed of Light: 5 Stocks Powering AI’s Optical Future

MarketBeat highlights NVIDIA’s broader photonics investment and says the global photonics market is about $1.25T, growing mid-single digits through the next decade, with silicon photonics rising ~30% annually. It profiles Aeluma (NASDAQ: ALMU), citing quantum-dot lasers and a manufacturing method that grows optical-quality substrate on silicon. The article notes Aeluma is pre-revenue, seeks data-center/defense partnerships for design wins and prototype certifications, and targets production and

$ALMUMedAI 8/10

Aeluma Sees Accelerated Timeline for Quantum Commercialization

Aeluma (NASDAQ: ALMU) said the U.S. Department of Commerce announced proposed CHIPS Act incentives of more than $2 billion for nine companies to accelerate quantum computing, shifting from R&D to manufacturing. Aeluma supported one company that signed a letter of intent, with involvement contingent on a subcontract. Aeluma cited its scalable wafer platform and recent U.S. contracts for quantum materials and lasers.